![](/wp-content/uploads/2019/05/fda-announcement.png)
$599
FDA Issues Final Guidance on Biosimilar Interchangeability
Late last week, FDA issued the final guidance on biosimilar interchangeability titled, “Considerations in Demonstrating Interchangeability With a Reference Product Guidance for Industry.” Below, FENIX provides thoughts on the FDA interchangeability guidance in the context of the insulin market.